 |
 |
 |
 |
 |
|
 |
 |
 |
 |
Distribution
Absorption Systems uses both in vitro and in vivo models to measure and classify the distribution of our customers' compounds.
We routinely run assays for our customers that determine, for example:
- the extent that a compound binds to the plasma proteins,
- the extent and rate at which a compound penetrates the blood-brain barrier,
- the pharmacokinetics of a compound in mice, rats, mini-pigs, dogs, and non-human primates.
A description of our various distribution related assays can be found in the Assay Data Sheets listed in the Related Literature section below. Click on the ones you want to download.
|
Please contact Absorption Sytems if you would like our help in determining the distribution properties of your compounds.
Related Literature
This assay is used to determine the blood-brain barrier (BBB) penetration potential of a test compound using MDR1-MDCK cell monolayers.
Click Here to Download
Equilibrium dialysis is used in this assay to determine the percentage of test compound that binds to human plasma proteins.
Click Here to Download
Equilibrium dialysis is used in this assay to determine the percentage of test compound that binds to rat plasma proteins.
Click Here to Download
Ultracentrifugation is used in this assay to determine the percentage of test compound that binds to plasma proteins.
Click Here to Download
Equilibrium dialysis is used in this assay to determine the percentage of test compound that binds to plasma proteins.
Click Here to Download
Determination of the fractional binding of test compound to plasma proteins using an ultrafiltration technique.
Click Here to Download
This assay is used to determine the unbound fraction of test compound in a rat brain homogenate via equilibrium dialysis.
Click Here to Download
This assay is used to determine the blood-to-plasma partition coefficient of a test compound in mice, rats, or humans in vitro.
Click Here to Download
This assay is used to determine the blood-to-plasma partition coefficient of a test compound in mice, rats, and humans in vitro.
Click Here to Download
This screening assay is used to determine the bioavailability of test compounds relative to a reference compound after oral administration to rats.
Click Here to Download
Determination of brain-to-plasma ratio of a test compound in rats or mice following IV or oral dosing.
Click Here to Download
This assay uses in situ brain perfusion to determine both the potential brain penetration of test compound and whether it is a P-gp substrate.
Click Here to Download
This assay is used to determine the absolute bioavailability of a test compound in mice.
Click Here to Download
This assay is used to determine the bioavailability of a test compound in dogs when the compound is administered by at least two different routes.
Click Here to Download
This screening assay is used to determine the bioavailability / exposure of test compounds after two routes of administration to male mice.
Click Here to Download
This screening assay is used to determine the bioavailability / exposure of test compounds after two routes of administration to male rats.
Click Here to Download
This assay is used to determine the bioavailability / exposure of test compounds in male dogs after two routes of administration.
Click Here to Download
This assay uses in vivo carotid infusion to determine the extent of brain penetration of test compound in a physiological setting, including plasma protein binding.
Click Here to Download
This assay is used to determine the bioavailability / exposure of a test compound in dogs after two routes of administration (non-crossover).
Click Here to Download
The benefits of knowing if your compound crosses the blood-brain barrier (BBB)
Click Here to Download
Brochures
In vitro, in situ, and in vivo models to assess brain penetration potential
Click Here to Download
Determination of exposure and bioavailability in preclinical species (rodents to primates)
Click Here to Download